Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Thoracic 1Other solid neoplasm 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Uterine Cervical Neoplasms 9Squamous Cell Carcinoma of Head and Neck 9Lung Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Oropharyngeal Neoplasms 6Nasopharyngeal Carcinoma 4Mesothelioma, Malignant 4Urinary Bladder Neoplasms 3Small Cell Lung Carcinoma 3Mouth Neoplasms 3Lymphoid Interstitial Pneumonia 3Laryngeal Neoplasms 3Carcinoma 3Adenocarcinoma of Lung 3Vaginal Neoplasms 2Triple Negative Breast Neoplasms 2Tongue Neoplasms 2Ovarian Neoplasms 2Hypopharyngeal Neoplasms 2Ganglioneuroblastoma 2Carcinoma, Transitional Cell 2Brenner Tumor 2Urethral Neoplasms 1Ureteral Neoplasms 1Stomach Neoplasms 1Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 1Solitary Fibrous Tumor, Pleural 1Sinonasal Squamous Cell Carcinoma 1Salivary Gland Neoplasms 1Resectable Intrahepatic Cholangiocarcinoma 1

Interventions

Specimen Handling 14Magnetic Resonance Spectroscopy 11Taxes 9Biopsy 9veliparib 7Paclitaxel 7Carboplatin 7pembrolizumab 3olaparib 3Cyclophosphamide 32,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3(2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone 3talazoparib 2eribulin 2entinostat 2cediranib 2Radiotherapy 2Radiation 2Platinum 2Nivolumab 2Irinotecan 2Immunoglobulin G 2Gemcitabine 2Doxorubicin 2Disulfides 2Cisplatin 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 21,2-diaminocyclohexaneplatinum II citrate 2tremelimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Triple Negative Breast Neoplasms × 1,2-diaminocyclohexaneplatinum II citrate × Clear all
NCT04491942 2026-04-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
74 enrolled
BreastGenitourinaryGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Penile Neoplasms, Triple Negative Breast Neoplasms

NCT02595905 2026-04-08

Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

National Cancer Institute (NCI)

Phase 2 Completed
344 enrolled 11 charts
BreastCNS

Brain Neoplasms, Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡